Drug Trial Radar · NCT03562169
The Role of Ixazomib in Autologous Stem Cell Transplant in Relapsed Myeloma - Myeloma XII (ACCoRd)
Last checked: Nov 20, 2026Latest source record: Jun 19, 2018 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
406
Planned (sponsor's estimate)
Start
Mar 20, 2017
Primary completion
Mar 2026
Study completion Mar 2027
Sponsor
- Lead sponsor
- University of LeedsAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Cancer Research UK; Takeda
- First posted
- Jun 19, 2018
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Study design: Randomised, controlled, multi-centre, open-label, phase III trial (with a single intervention registration phase). Primary Objectives The primary objectives of this study are to determine: * The impact on Depth of Response (DoR: less than VGPR versus VGPR or better) when salvage ASCT conditioning is augmented by the addition of a proteasome inhibitor * The influence of a consolidation and maintenance strategy on the Durability of Response (DuR:PFS) Secondary objectives The secondary objectives of this study are to determine: * Overall survival * Time to disease progression * The overall response rate following ixazomib, thalidomide and dexamethasone (ITD) re-induction * Time to next treatment * Progression-free survival 2 (PFS2) * Duration of response * Minimal Residual Disease (MRD) negative rate post re-induction, post-ASCT and conversion after ITD consolidation * Engraftment kinetics * Toxicity and safety * Quality of life (QoL) Participant population (refer to protocol section 9 for a full list of eligibility criteria). * Relapsed MM (with measurable disease by IMWG criteria) previously treated with ASCT * First progressive disease (PD) at least 12 months since first ASCT, requiring therapy. * ECOG Performance Status 0-2 * Aged at least 18 years * Adequate full blood count and renal, hepatobiliary, pulmonary and cardiac function * Written informed consent Interventions: All participants will be registered at trial entry and will receive re-induction therapy with 4-6, 28-day cycles of ixazomib, thalidomide and dexamethasone (ITD), in order to reach maximum response. Participants who achieve at least stable disease (SD) will be randomised on a 1:1 basis to receive either conventional ASCT (ASCTCon), using melphalan, or augmented ASCT (ASCTAug), using melphalan with ixazomib. All participants achieving or maintaining a minimal response (MR) or better following trial ASCT will undergo a second randomisation to consolidation and maintenance or no further treatment. Participants randomised to consolidation and maintenance will receive treatment as follows: consolidation with 2 cycles of ITD and maintenance with ixazomib until disease progression. Number of participants: 406 participants will be registered into the trial to allow 284 participants to be randomised at the first randomisation (R1) and 248 participants to be randomised at the second randomisation (R2).
Conditions
- Multiple Myeloma
Interventions
Ixazomib, thalidomide, & dexamethasone (ITD) re-inductionDrug
4 - 6 ITD 28-day cycles as follows: * Ixazomib 4mg capsule on days 1, 8 and 15 * Thalidomide 100mg capsule on days 1-28 * Dexamethasone 40mg tablets on days 1, 8, 15 and 22
Conventional autologous stem cell transplant (ASCT-con)Drug
Melphalan 200mg/m2 IV infusion on Day -1, followed by ASCT on Day 0.
Augmented autologous stem cell transplant (ASCT-aug)Drug
Melphalan 100mg/m2 IV infusion on Day -3 and Day -2 plus ixazomib 4mg capsules on Day -4 and Day -1. ASCT will then be given on Day 0.
ITD consolidation and ixazomib maintenance vs. No further therapyDrug
Participants will be randomised to either 'no further therapy' or 'ITD consolidation and ixazomib maintenance'. Participants randomised to 'no further treatment' will not receive any further treatment but will be followed up at 8 weeks post randomisation 2 and at 3-monthly clinic visits until disease progression. Participants randomised to ITD consolidation and ixazomib maintenance will receive: Two 28-day cycles of ITD consolidation (same doses as in ITD re-induction). This will be followed by ixazomib maintenance as follows: Ixazomib 4mg capsule on days 1, 8 and 15 of each 28-day cycle until disease progression.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Overall response rateTime frame: 100 days post-ASCT
- Progression-free survivalTime frame: From date of registration to date of disease progression, up to 120 months.
Locations
91 sites in 1 country. Site status is shown where the registry gives one.
Aberdeen Royal Infirmary
Aberdeen, United Kingdom · Recruiting
Monklands Hospital
Airdrie, United Kingdom · Recruiting
University Hospital Ayr
Ayr, United Kingdom · Recruiting
Barnsley Hospital
Barnsley, United Kingdom · Recruiting
Basingstoke & North Hampshire Hospital
Basingstoke, United Kingdom · Recruiting
Royal United Hospital
Bath, United Kingdom · Recruiting
Good Hope Hospital
Birmingham, United Kingdom · Recruiting
Heartlands Hospital
Birmingham, United Kingdom · Recruiting
Queen Elizabeth Hospital
Birmingham, United Kingdom · Recruiting
Blackpool Victoria Hospital
Blackpool, United Kingdom · Recruiting
Pilgrim Hospital
Boston, United Kingdom · Recruiting
Royal Bournemouth Hospital
Bournemouth, United Kingdom · Recruiting
Bradford Royal Infirmary
Bradford, United Kingdom · Recruiting
Bristol Haematology & Oncology Centre
Bristol, United Kingdom · Recruiting
Southmead Hospital
Bristol, United Kingdom · Recruiting
Queen's Hospital
Burton-on-Trent, United Kingdom · Recruiting
Addenbrooke's Hospital
Cambridge, United Kingdom · Recruiting
St Helier Hospital
Carshalton, United Kingdom · Recruiting
Cheltenham General Hospial
Cheltenham, United Kingdom · Recruiting
Countess of Chester Hospital
Chester, United Kingdom · Recruiting
Chesterfield Royal Hospital
Chesterfield, United Kingdom · Recruiting
St Richards Hospital
Chichester, United Kingdom · Recruiting
University Hospital Coventry
Coventry, United Kingdom · Recruiting
Royal Derby Hospital
Derby, United Kingdom · Recruiting
Dewsbury Hospital
Dewsbury, United Kingdom · Recruiting
Russells Hall Hospital
Dudley, United Kingdom · Recruiting
Ninewells Hospital
Dundee, United Kingdom · Recruiting
Hairmyres Hospital
East Kilbride, United Kingdom · Recruiting
Western General Hospital
Edinburgh, United Kingdom · Recruiting
Beatson Cancer Centre
Glasgow, United Kingdom · Recruiting
New Victoria Hospital
Glasgow, United Kingdom · Recruiting
Gloucestershire Royal Hospital
Gloucester, United Kingdom · Recruiting
Grantham and District Hospital
Grantham, United Kingdom · Recruiting
Diana Princess of Wales Hospital
Grimsby, United Kingdom · Recruiting
Calderdale Royal Hospital
Halifax, United Kingdom · Recruiting
Harrogate District Hospital
Harrogate, United Kingdom · Recruiting
Huddersfield Royal Infirmary
Huddersfield, United Kingdom · Recruiting
Castle Hill Hospital
Hull, United Kingdom · Recruiting
Raigmore Hospital
Inverness, United Kingdom · Recruiting
Ipswich Hospital
Ipswich, United Kingdom · Recruiting
Showing 40 of 91 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.